|
|
|
|
|
|
|
10.02.26 - 11:24
|
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes (PBR)
|
|
|
The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation. Through this arrangement, Takeda will
The post Takeda and Iambic announce $1.7bn deal to advance small molecule programmes appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.01.26 - 07:42
|
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead (Business Wire)
|
|
|
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE® Generics is Tapering Off
Core Operating Profit Declined by 3.4% at both CER and AER Year to Date
Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been updated primarily due to the impact of VYVANSE generics.
Takeda is positioned for long-term growth and has multiple late-stage programs with multibillion-dollar peak revenue...
|
|
|
|
|
|
|
14.01.26 - 06:12
|
Ascentage: Partnership With Takeda Going Well (Bloomberg)
|
|
|
Dajun Yang, Co-founder, Chairman and CEO at Ascentage Pharma, says he hopes the company's partnership with Takeda on a blood cancer therapy could be ready for commercialization in two years. He speaks on "Bloomberg: The China Show" ahead of his presentation at the JPMorgan Healthcare Conference in San Francisco. (Source: Bloomberg)...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
